Free Trial
NASDAQ:ORMP

Oramed Pharmaceuticals (ORMP) Stock Price, News & Analysis

Oramed Pharmaceuticals logo
$3.71 -0.32 (-7.94%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$3.72 +0.01 (+0.27%)
As of 11/13/2026 07:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Oramed Pharmaceuticals Stock (NASDAQ:ORMP)

Advanced

Key Stats

Today's Range
$3.67
▼
$4.12
50-Day Range
$3.71
▼
$5.01
52-Week Range
$2.25
▼
$5.47
Volume
160,814 shs
Average Volume
118,604 shs
Market Capitalization
$154.32 million
P/E Ratio
0.60
Dividend Yield
6.74%
Price Target
N/A
Consensus Rating
Buy

Company Overview

Oramed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company developing oral drug-delivery technologies. Its platform is designed to protect protein-based medicines as they pass through the digestive system and support their absorption, with the aim of delivering medicines by mouth that have traditionally been given by injection.

The company’s research has focused on oral treatments for metabolic conditions, including ORMD-0801, an oral insulin candidate, and an oral GLP-1 candidate. These products are investigational; Oramed does not market them as approved treatments.

Founded in 2006, Oramed has operations in the United States and Israel. Nadav Kidron serves as the company’s president and chief executive officer.

AI Generated. May Contain Errors.

Oramed Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
51st Percentile Overall Score

ORMP MarketRank™: 
2.552534804305 of 5 stars

Oramed Pharmaceuticals scored higher than 51% of companies evaluated by MarketBeat, and ranked 537th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Oramed Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Oramed Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Oramed Pharmaceuticals' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Oramed Pharmaceuticals is 0.60, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.40.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Oramed Pharmaceuticals is 0.60, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.56.

  • Price to Book Value per Share Ratio

    Oramed Pharmaceuticals has a P/B Ratio of 0.74. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    4.08% of the float of Oramed Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Oramed Pharmaceuticals has a short interest ratio ("days to cover") of 11.34, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Oramed Pharmaceuticals has recently decreased by 7.42%, indicating that investor sentiment is improving significantly.
  • Dividend Leadership

    Oramed Pharmaceuticals is a leading dividend payer. It pays a dividend yield of 6.20%, putting its dividend yield in the top 25% of dividend-paying stocks.

  • Dividend Growth

    Oramed Pharmaceuticals does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Oramed Pharmaceuticals is 4.06%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Read more about Oramed Pharmaceuticals' dividend.
  • News Sentiment

    Oramed Pharmaceuticals has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Oramed Pharmaceuticals this week, compared to 1 article on an average week.
  • Search Interest

    Only 1 people have searched for ORMP on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Oramed Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $225,500.00 in company stock.

  • Percentage Held by Insiders

    20.77% of the stock of Oramed Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    12.73% of the stock of Oramed Pharmaceuticals is held by institutions.

  • Read more about Oramed Pharmaceuticals' insider trading history.
Receive ORMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ORMP Stock News Headlines

Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
Oramed Pharmaceuticals (ORMP) Set to Release Earnings on Thursday
Oramed: Q2 Earnings Snapshot
See More Headlines

ORMP Stock Analysis - Frequently Asked Questions

Oramed Pharmaceuticals' stock was trading at $2.85 on January 1st, 2026. Since then, ORMP shares have increased by 30.2% and is now trading at $3.71.

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) issued its quarterly earnings data on Thursday, November, 12th. The biotechnology company reported ($0.16) EPS for the quarter, missing the consensus estimate of $0.43 by $0.59.

Oramed Pharmaceuticals' top institutional investors include Aquamarine Financial Cayman Ltd (6.38%), BML Capital Management LLC (2.13%), State Street Corp (1.12%) and Ritholtz Wealth Management (0.16%). Insiders that own company stock include Joshua Hexter and Avraham Gabay.
View institutional ownership trends
.

Shares of ORMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oramed Pharmaceuticals investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Palantir Technologies (PLTR), NIO (NIO), Intel (INTC) and Micron Technology (MU).

Company Calendar

Last Earnings
11/12/2026
Today
11/15/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ORMP
CIK
1176309
Employees
13
Year Founded
2006

Profitability

EPS (Trailing Twelve Months)
$6.16
Trailing P/E Ratio
0.60
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$64.05 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-7.57%
Return on Assets
-6.58%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.98
Quick Ratio
4.98

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
$0.08 per share
Price / Cash Flow
44.42
Book Value
$5.02 per share
Price / Book
0.74

Miscellaneous

Outstanding Shares
41,597,000
Free Float
32,957,000
Market Cap
$154.32 million
Optionable
Optionable
Beta
1.31

Social Links

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

This page (NASDAQ:ORMP) was last updated on 11/13/2026 by MarketBeat.com Staff.
From Our Partners